Bb5a31f81ClaimTraditional drug development relies on empirical trial-and-error screening processes rather than predictive computational modelingAgreeDisagree
Bb5a31f81ClaimIsomorphic Labs partners with biopharmaceutical companies to apply its artificial intelligence drug design engine to partner drug targetsAgreeDisagree
Bb5a31f81ClaimAs of November 2026, the average development cost of a new drug has risen to approximately 1.5 billion dollarsAgreeDisagree
Bb5a31f81ClaimMost candidate drugs fail during human clinical trials rather than during preclinical in-vitro researchAgreeDisagree
Bb5a31f81ClaimIsomorphic Labs utilizes automated laboratories to generate experimental data to power computational modelsAgreeDisagree
Bb5a31f81ClaimIsomorphic Labs internally prioritizes drug discovery programs targeting oncology, immunology, and inflammationAgreeDisagree
Bb5a31f81ClaimDeveloping a new drug traditionally takes approximately 15 years from initial discovery to regulatory approvalAgreeDisagree
Bb5a31f81ClaimAutomated wet laboratories and robotic platforms remain constrained by physical reaction rates and cell culturing timesAgreeDisagree
Bb5a31f81ClaimDrug regulatory frameworks historically mandated testing candidate molecules on rats and other animals before human clinical trialsAgreeDisagree
Bb5a31f81ClaimTraditional pharmaceutical research typically treats each drug program as a bespoke project, limiting transferable learnings to subsequent programsAgreeDisagree
Bb5a31f81ClaimData repositories from historical pharmaceutical research often reflect biased sampling that limits machine learning model generalizationAgreeDisagree
Bb5a31f81ClaimRevolution Medicines developed the KRAS inhibitor daraxonrasib to treat late-stage pancreatic cancer patientsAgreeDisagree
Bb5a31f81ClaimPrecise molecular engineering aims to eliminate off-target liver toxicity to permit the simultaneous administration of multidrug cocktailsAgreeDisagree
Bb5a31f81ClaimIsomorphic Labs maintains an internal proprietary drug discovery pipeline that Isomorphic Labs fully owns and fundsAgreeDisagree
Bb5a31f81ClaimIsomorphic Labs relies on physical laboratory experiments primarily for hypothesis validation rather than iterative discoveryAgreeDisagree
Bb5a31f81ClaimApproximately 10% of experimental drug candidates successfully pass clinical trialsAgreeDisagree
Bb5a31f81ClaimAntisense oligonucleotides are short RNA molecules designed to bind target RNA transcripts to modify splicing or gene expressionAgreeDisagree
Bb5a31f81ClaimGLP-1 receptor agonist medications suppress appetite by targeting neural signaling pathways that regulate hunger and body weight settling pointsAgreeDisagree
Bb5a31f81ClaimMailgun co-founder Ev stated that 90 percent of Mailgun's research and development resources were dedicated to combating abusive sendersAgreeDisagree
Bb5a31f81ClaimAxon continued research and development on remotely operated TASER-equipped drones following the June 2022 ethics board resignationsAgreeDisagree